• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2023年中国广东省女性乳腺癌和宫颈癌的发病率、死亡率及终生风险趋势

Trends in the Incidence, Mortality and Lifetime Risks of Female Breast and Cervical Cancer - Guangdong Province, China, 2023.

作者信息

Liao Yu, Zhu Qian, Sun Kexin, Zheng Rongshou, Deng Huihong, Lin Lifeng, Meng Ruilin, Wei Wenqiang, Wang Ye

机构信息

Guangdong Provincial Center for Disease Control and Prevention, Guangzhou City, Guangdong Province, China.

Office for Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

China CDC Wkly. 2025 Jul 11;7(28):940-946. doi: 10.46234/ccdcw2025.157.

DOI:10.46234/ccdcw2025.157
PMID:40671699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12259474/
Abstract

INTRODUCTION

This study aims to report the epidemiological trends and provide updated estimates and lifetime risks for breast and cervical cancers among women in Guangdong province.

METHODS

A Bayesian age-period-cohort model was applied to project incidence and mortality rates for 2023. The adjusted for multiple primaries (AMP) method was used to calculate the lifetime risks of developing and dying from breast and cervical cancer. Joinpoint analysis was employed to describe the temporal trends.

RESULTS

The age-standardized incidence rate (ASIR) of female breast cancer increased from 2012 to 2019 in Guangdong province, with a particularly pronounced increase noted in the rural areas. The ASIR for cervical cancer among women aged over 55 increased in both urban and rural areas, whereas a declining trend was observed among women under the age of 55. The age-standardized mortality rates (ASMRs) for both breast cancer and cervical cancer demonstrated upward trends among women aged over 55, while no significant trend in ASMR was found for women under 55 years. In 2023, the estimated incidence rates of breast cancer and cervical cancer would be 50.81/10 (ASIR would be 35.57/10) and 15.31/10 (ASIR would be 10.41/10) respectively, with corresponding mortality rates of 10.78/10 (ASMR would be 7.15/10) and 6.11/10 (ASMR would be 3.93/10) for these cancers.

CONCLUSIONS

Breast cancer continues to pose a significant threat to women's health in both rural and urban areas of Guangdong, whereas cancer prevention and control programs for cervical cancer have shown positive impacts among the younger population. Greater emphasis should be placed on women aged over 55 to halt the rising mortality rates of both cancers within this population.

摘要

引言

本研究旨在报告广东省女性乳腺癌和宫颈癌的流行病学趋势,并提供最新的发病率估计值和终生风险。

方法

应用贝叶斯年龄-时期-队列模型预测2023年的发病率和死亡率。采用多原发调整(AMP)方法计算患乳腺癌和宫颈癌以及死于这两种癌症的终生风险。运用Joinpoint分析描述时间趋势。

结果

2012年至2019年期间,广东省女性乳腺癌的年龄标准化发病率(ASIR)有所上升,农村地区的上升尤为明显。55岁以上女性宫颈癌的ASIR在城乡地区均有所上升,而55岁以下女性则呈下降趋势。55岁以上女性乳腺癌和宫颈癌的年龄标准化死亡率(ASMR)均呈上升趋势,而55岁以下女性的ASMR未发现明显趋势。2023年,乳腺癌和宫颈癌的估计发病率分别为50.81/10(ASIR为35.57/10)和15.31/10(ASIR为10.41/10),这两种癌症的相应死亡率分别为10.78/10(ASMR为7.15/10)和6.11/10(ASMR为3.93/10)。

结论

乳腺癌继续对广东省城乡女性的健康构成重大威胁,而宫颈癌防控项目在年轻人群中已显示出积极影响。应更加重视55岁以上的女性,以遏制该人群中这两种癌症死亡率的上升。

相似文献

1
Trends in the Incidence, Mortality and Lifetime Risks of Female Breast and Cervical Cancer - Guangdong Province, China, 2023.2023年中国广东省女性乳腺癌和宫颈癌的发病率、死亡率及终生风险趋势
China CDC Wkly. 2025 Jul 11;7(28):940-946. doi: 10.46234/ccdcw2025.157.
2
Trends of Female Breast Cancer Incidence, Mortality, and Survival in Fujian Province of China: 2011-2020 and Projection to 2025.中国福建省女性乳腺癌的发病率、死亡率及生存率趋势:2011 - 2020年及2025年预测
Cancer Med. 2025 Jul;14(13):e71033. doi: 10.1002/cam4.71033.
3
Prophylactic mastectomy for the prevention of breast cancer.预防性乳房切除术用于预防乳腺癌。
Cochrane Database Syst Rev. 2004 Oct 18(4):CD002748. doi: 10.1002/14651858.CD002748.pub2.
4
Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis.2022年东南亚地区癌症发病率和死亡率估计:一项比较分析。
Lancet Oncol. 2025 Apr;26(4):516-528. doi: 10.1016/S1470-2045(25)00017-8. Epub 2025 Feb 27.
5
Incidence and disability-adjusted life-years of infective endocarditis in China from 1990 to 2021: comparison with G20 based on the Global Burden of Disease Study 2021.1990年至2021年中国感染性心内膜炎的发病率和伤残调整生命年:基于《2021年全球疾病负担研究》与二十国集团的比较
BMJ Open. 2025 Jul 6;15(7):e094490. doi: 10.1136/bmjopen-2024-094490.
6
Analysis of trends in the burden of colorectal cancer in China and globally from 1990 to 2021 with projections for the next 15 years: a cross-sectional study based on the GBD database.1990年至2021年中国及全球结直肠癌负担趋势分析及未来15年预测:基于全球疾病负担(GBD)数据库的横断面研究
Front Public Health. 2025 May 26;13:1518536. doi: 10.3389/fpubh.2025.1518536. eCollection 2025.
7
Trends and projections of the burden of gastric cancer in China and G20 countries: a comparative study based on the global burden of disease database 2021.中国和二十国集团(G20)国家胃癌负担的趋势与预测:基于2021年全球疾病负担数据库的比较研究
Int J Surg. 2025 May 12. doi: 10.1097/JS9.0000000000002464.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
9
HPV cancer burden by anatomical site, country, and region in 2022.2022年按解剖部位、国家和地区划分的人乳头瘤病毒相关癌症负担
Sci Rep. 2025 Jul 1;15(1):21048. doi: 10.1038/s41598-025-06700-8.
10
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.

本文引用的文献

1
Lifetime probabilities of developing and dying from cancer in China: comparison with Japan and the United States in 2022.中国癌症发病和死亡的终生概率:与2022年日本和美国的比较。
Sci China Life Sci. 2025 May;68(5):1478-1486. doi: 10.1007/s11427-024-2810-y. Epub 2025 Feb 26.
2
Cancer incidence and mortality in China, 2022.2022年中国癌症发病率与死亡率
J Natl Cancer Cent. 2024 Feb 2;4(1):47-53. doi: 10.1016/j.jncc.2024.01.006. eCollection 2024 Mar.
3
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
4
Global, regional, and national lifetime probabilities of developing cancer in 2020.2020 年全球、区域和国家终生患癌概率。
Sci Bull (Beijing). 2023 Nov 15;68(21):2620-2628. doi: 10.1016/j.scib.2023.09.041. Epub 2023 Sep 29.
5
Breast Cancer Screening Coverage - China, 2018-2019.2018 - 2019年中国乳腺癌筛查覆盖率
China CDC Wkly. 2023 Apr 14;5(15):321-326. doi: 10.46234/ccdcw2023.062.
6
Trends in Incidence Rates, Mortality Rates, and Age-Period-Cohort Effects of Female Breast Cancer - China, 2003-2017.2003 - 2017年中国女性乳腺癌发病率、死亡率及年龄 - 时期 - 队列效应趋势
China CDC Wkly. 2023 Apr 14;5(15):340-346. doi: 10.46234/ccdcw2023.065.
7
Cervical Cancer Screening Coverage - China, 2018-2019.2018 - 2019年中国宫颈癌筛查覆盖率
China CDC Wkly. 2022 Dec 2;4(48):1077-1082. doi: 10.46234/ccdcw2022.217.
8
Trends in Incidence Rates, Mortality Rates, and Age-Period-Cohort Effects of Cervical Cancer - China, 2003-2017.2003 - 2017年中国宫颈癌发病率、死亡率及年龄 - 时期 - 队列效应趋势
China CDC Wkly. 2022 Dec 2;4(48):1070-1076. doi: 10.46234/ccdcw2022.216.
9
The prevalence and increasing trends of overweight, general obesity, and abdominal obesity among Chinese adults: a repeated cross-sectional study.中国成年人超重、普遍肥胖和腹型肥胖的流行率和增长趋势:一项重复横断面研究。
BMC Public Health. 2019 Oct 15;19(1):1293. doi: 10.1186/s12889-019-7633-0.
10
Prevalence of human papillomavirus infection in Guangdong Province, China: a population-based survey of 78,355 women.中国广东省人乳头瘤病毒感染的患病率:一项基于78355名女性的人群调查。
Sex Transm Dis. 2014 Dec;41(12):732-8. doi: 10.1097/OLQ.0000000000000201.